Loading
A phase 3 trial of Megestrol acetate in non-small-cell lung cancer, run by Changchun GeneScience Pharmaceutical Co., Ltd., now recruiting.
Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT07150663 by Changchun GeneScience Pharmaceutical Co., Ltd., with 134 participants planned, started 2025-08-20 and due to reach its primary completion in 2027-06-30. Interventions recorded: Nano-crystalline Megestrol Acetate Oral Suspension.
Shares Megestrol acetate and the tag pipeline.
Shares Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.